#101: The Future of Psychedelic Medicine with Dr. Matthew Johnson

Psychedelic researcher Dr. Matthew Johnson from Johns Hopkins University joins Dr. Mike Hart to delve deep into the world of psychedelics. Their discussion extends from the therapeutic potential of psychedelic substances in treating mental health disorders such as depression, PTSD, and addiction, to the controversy surrounding their use. Dr. Johnson shares his experiences in pioneering psychedelic research, the therapeutic model he's developing, and insights into the microdosing and macrodosing of substances. They touch upon the societal impact of alcohol and drug misuse, the power of the placebo effect, and how psychedelics interact with traditional treatments like SSRIs. The episode concludes with a nuanced look at the challenges and future direction of the psychedelic space.

Time-codes:

[00:00:00] Dr. Mike Hart introduces Dr. Matthew Johnson. Johnson's work in the psychedelic field is presented, setting the stage for the conversation.

[00:02:10] Dr. Hart highlights the growing interest in using psychedelics as treatments for mental health conditions, opening the floor for a deep discussion on the potential of these substances.

[00:07:57] Dr. Johnson delves into historical LSD research related to alcoholism, sparking interest in the anti-addiction potential of psychedelics.

[00:15:42] Discussion around the potential therapeutic effects of microdosing psychedelics, including its potential role in treating depression and the possible influence of the placebo effect.

[00:24:02] Johnson elucidates on the process of "integration" in psychedelic therapy, which involves understanding the implications of psychedelic experiences for one's psychiatric issues.

[00:30:30] Dr. Johnson introduces the concept of a generalized psychedelic therapy model, suggesting its applicability across various mental disorders.

[00:32:30] An insight into Dr. Johnson's survey work on the therapeutic use of psychedelics, where people have quit or reduced their consumption of harmful substances.

[00:36:59] Dr. Johnson underscores that different psychedelics have similar efficacy rates regardless of the treated condition, leading to a deeper understanding of their impact.

[00:42:30] Discussion on how the synchronization of different brain areas could enhance creativity, touching upon a less-explored benefit of psychedelic use.

[00:49:28] Dr. Johnson discusses the overuse of certain medications like SSRIs and ADHD drugs, while stressing that he does not advocate for their complete removal from the treatment toolbox.

[00:53:31] Dr. Johnson addresses the problem of puritanism in the psychedelic space and its impact on recognizing other effective treatments.

[01:03:00] Dr. Johnson talks about the effect of antidepressants on the psychedelic experience, providing critical information for those on such treatments considering psychedelic therapy.

[01:05:30] They discuss the challenges of withdrawing from prescribed medications for alternative treatments like Ayahuasca, acknowledging the complexities faced by patients.

[01:10:37] Matthew Johnson shares his experience at a psychedelic conference, introducing the audience to a broader context of the psychedelic space.

[01:13:15] Johnson expresses concerns about future developments in the psychedelic field, alluding to accusations against MAPS, making for an intriguing and thought-provoking ending.